Patrik Brundin
39 results.
For the estimated between 7 million and 10 million people living with Parkinson’s disease, there’s new reason for hope: Van Andel Research…
GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of…
GRAND RAPIDS, Mich. (Aug. 8, 2016)—They’re two of the biggest mysteries in Parkinson’s disease research—where does the disease start? And how can it be stopped…
GRAND RAPIDS, Mich. (July 27, 2016)—Clues that point toward new risk mechanisms for developing Parkinson’s disease are hiding in some unusual spots, according to
Note: To read the commentary published in the Journal of Parkinson's Disease click here.
Investigators will focus on safety for long-term use in non-cancer…
By Patrik Brundin, M.D., Ph.D.
Director, Center for Neurodegenerative Science
The time has come to shift the paradigm on Parkinson’s disease.
Never before have…
GRAND RAPIDS, Mich. (February 22, 2016)—A medication approved to treat various respiratory diseases and that has demonstrated neuroprotective effects in preclinical studies is the focus…
GRAND RAPIDS, Mich. (June 2, 2015)—Van Andel Research Institute and the Netherlands-based ParkinsonNet today took the first steps toward broadening an initiative that will benefit…